You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tislelizumab

Showing 1 - 25 of 139
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Oct 14, 2022

Recurrent Hepatocellular Carcinoma Trial in Guangzhou (Tislelizumab, Tislelizumab combined with Levatinib)

Recruiting
  • Recurrent Hepatocellular Carcinoma
  • Tislelizumab
  • Tislelizumab combined with Levatinib
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Mar 31, 2022

Immunotherapy Trial (Tislelizumab, Capecitabine, oxaliplatin)

Not yet recruiting
  • Immunotherapy
  • Tislelizumab
  • +4 more
  • (no location specified)
Jul 28, 2022

Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Tislelizumab
  • +3 more
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Institute & Hospital
May 24, 2022

Nasopharyngeal Carcinoma Trial in Beijing (Tislelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Tislelizumab
  • Beijing, Beijing, China
    National Cancer Center /National Clinical Research Center for Ca
Jul 4, 2022

Esophageal Cancer Trial (Tislelizumab, Radiation, Paclitaxel)

Not yet recruiting
  • Esophageal Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Nov 18, 2022

Stage III NSCLC Trial in Guangzhou (Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy)

Recruiting
  • Stage III Non-small Cell Lung Cancer
  • Neoadjuvant chemo-immunotherapy
  • +5 more
  • Guangzhou, China
    Sun Yat-sen University
Jul 19, 2022

Pancreatic Tumors Trial (Tislelizumab)

Not yet recruiting
  • Pancreatic Neoplasms
  • Tislelizumab
  • (no location specified)
Dec 26, 2022

Non Small Cell Lung Cancer Trial (Tislelizumab, Ociperlimab, LBL-007)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Tislelizumab
  • +2 more
  • (no location specified)
Jan 30, 2023

Lung Cancer, Small Cell Trial in Hangzhou (Tislelizumab, Sitravatinib)

Recruiting
  • Lung Cancer, Small Cell
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 13, 2022

Melanoma Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Not yet recruiting
  • Melanoma
  • Tislelizumab
  • +2 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 4, 2022

Immunotherapy Esophagus Cancer Trial (Tislelizumab, Albumin paclitaxel, Nedaplatin)

Not yet recruiting
  • Immunotherapy Esophagus Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • Tislelizumab
  • (no location specified)
Jul 28, 2022

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Head Neck Cancer Trial in Chengdu, Tianjin (Tislelizumab, Pulse radiation)

Recruiting
  • Head and Neck Cancer
  • Tislelizumab
  • Pulse radiation
  • Chengdu, Sichuan, China
  • +1 more
Oct 25, 2022

Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma Trial in Nanjing (Tislelizumab, 5-FU, cis Platinum)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Locally Advanced Carcinoma
  • Tislelizumab
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Jul 19, 2022

Cervical Cancer Trial in Nanning (tislelizumab, concurrent chemoradiotherapy)

Not yet recruiting
  • Cervical Cancer
  • tislelizumab
  • concurrent chemoradiotherapy
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Aug 22, 2022

Carcinoma, Hepatocellular, Liver Cell Carcinoma Trial in New Brunswick (Tislelizumab)

Not yet recruiting
  • Carcinoma, Hepatocellular
  • Liver Cell Carcinoma
  • Tislelizumab
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
May 4, 2022

Head and Neck Squamous Cell Carcinoma Trial (Nab-paclitaxel, Cisplatin, Tislelizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Aug 23, 2022

Pancreatic Cancer Trial in Baltimore (Tislelizumab, SX-682)

Not yet recruiting
  • Pancreatic Cancer
  • Baltimore, Maryland
    Johns Hopkins SKCCC
Jan 23, 2023

Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Tislelizumab
  • +4 more
  • Wuhan, Hubei, China
  • +2 more
Jan 16, 2023

NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

Recruiting
  • NSCLC, Stage III
  • Tislelizumab
  • +2 more
  • Beijing, Beijing, China
    Beijing Tsinghua Chang Gung Hospital
Nov 4, 2022

Uterine Cervical Tumors Trial in Nanning (Tislelizumab, DDP synchronous with radiotherapy)

Recruiting
  • Uterine Cervical Neoplasms
  • Tislelizumab
  • DDP synchronous with radiotherapy
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Oct 19, 2022

Advanced Non-small-cell Lung Cancer Trial in Fuzhou (Tislelizumab)

Enrolling by invitation
  • Advanced Non-small-cell Lung Cancer
  • Tislelizumab
  • Fuzhou, Fujian, China
    Fujian cancer hospital
Jan 13, 2022

Muscle Invasive Bladder Cancer, Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab paclitaxel)

Active, not recruiting
  • Muscle Invasive Bladder Cancer
  • Urothelial Carcinoma
  • Tislelizumab
  • Nab paclitaxel
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Jun 8, 2022